Skip to main content

Moderna Inc. (MRNA) Stock

Moderna Inc. Stock Details, Movements and Public Alerts

Stock Details

Moderna Inc. (MRNA), a prominent company in the life sciences sector within the biological products, (no disgnostic substances) industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $31.65. Over the past 52 weeks, it has ranged between $23.15 and $126.42. This places the current price at 25.0% of its 52-week high and 36.7% above its 52-week low. Recent trading volume was recorded at 987. The International Securities Identification Number (ISIN) for this stock is US60770K1079.

Market Cap

$10.50B

52-Week High

$126.42

-74.96% from high

52-Week Low

$23.15

+36.72% from low

Avg Daily Volume

987

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

32.47

PEG Ratio

0.00

Potentially undervalued

Price to Book

1.04

EV/EBITDA

4.64

EPS (TTM)

-$8.73

Price to Sales

3.31

Beta

1.86

More volatile than market

How is MRNA valued relative to its earnings and growth?
Valuation data is not available for this stock.
What is MRNA's risk profile compared to the market?
With a beta of 1.86, Moderna Inc. is significantly more volatile than the market. For every 10% market move, this stock tends to move 19% in the same direction. Higher beta stocks offer greater potential returns but with increased risk. The price-to-book ratio of 1.04 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-105.70%

Operating Margin

-972.00%

Return on Equity

-29.30%

Return on Assets

-15.80%

Revenue Growth (YoY)

-35.30%

Earnings Growth (YoY)

-85.10%

How profitable and efficient is MRNA's business model?
Moderna Inc. achieves a profit margin of -105.70%, meaning it retains $-105.70 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -972.00% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -29.30% and ROA at -15.80%, the company achieves moderate returns on invested capital.
What are MRNA's recent growth trends?
Moderna Inc.'s revenue declined by 35.30% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings decreased by 85.10% year-over-year, reflecting the bottom-line impact of business performance. These growth metrics should be evaluated against BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry averages for proper context.

Company Size & Market

Shares Outstanding

386.74M

Book Value/Share

$26.01

Asset Type

Common Stock

What is MRNA's market capitalization and position?
Moderna Inc. has a market capitalization of $10.50B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 386.74M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry, it competes with other firms in this sector.
How does MRNA's price compare to its book value?
Moderna Inc.'s book value per share is $26.01, while the current stock price is $31.65, resulting in a price-to-book (P/B) ratio of 1.22. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$47.59

50.36% upside potential

Analyst Recommendations

Strong Buy

1

Buy

5

Hold

17

Sell

1

Strong Sell

3

How reliable are analyst predictions for MRNA?
27 analysts cover MRNA with 22% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The bearish sentiment could create opportunity if analysts are wrong. The consensus target of $47.59 implies 50.4% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on MRNA?
Current analyst recommendations:1 Strong Buy, 5 Buy, 17 Hold, 1 Sell, 3 Strong Sell. The neutral stance suggests uncertainty or fair valuation at current levels.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 02:22 AM

Technical Indicators

What does MRNA's RSI value tell investors?
RSI data is not available for this stock.
How should traders interpret MRNA's MACD and moving average crossovers?
MACD and moving average data are not available for this stock.

No technical indicators available yet.

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for MRNA and get notified when the price changes.

Stay Ahead of the Market with Moderna Inc. Alerts

Set up price alerts for Moderna Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.